Aquestive Therapeutics Files 8-K Furnishing Investor Presentation

What Happened Aquestive Therapeutics, Inc. filed a Current Report on Form 8-K on September 25, 2026 (Items 7.01 and 9.01) to furnish an investor presentation disclosed under Regulation FD. The presentation, dated September 23, 2026, is attached as Exhibit 99.1 to the filing and the report was signed by CFO A. Ernest Toth, Jr. The company noted the disclosed information may be amended or updated in future filings.

Key Details

• Filing date: September 25, 2026 (Form 8-K, Items 7.01 and 9.01).
• Investor presentation dated: September 23, 2026; attached as Exhibit 99.1.
• Disclosure type: Regulation FD furnishing of investor presentation to institutional investors, analysts and others.
• Report signed by: A. Ernest Toth, Jr., Chief Financial Officer.

Why It Matters This filing formally distributes Aquestive’s investor presentation to the market under Regulation FD, so institutional investors and analysts have access to the same disclosed material. Retail investors should review Exhibit 99.1 in the SEC filing for any operational, financial or strategic updates the company chose to present, and note that the company may update this information in future filings.